ReferenceMetabolic & incretin research
Semaglutide
Ozempic-class research peptide · Wegovy-class research peptide · GLP-1 agonist
Long-acting GLP-1 receptor agonist — the most-referenced single-incretin peptide in metabolic research.
About Semaglutide
Semaglutide is a long-acting GLP-1 receptor agonist and one of the most widely referenced incretin peptides in the research literature. In laboratory research it serves as the benchmark GLP-1 agonist against which dual and triple agonists are compared. TagPep is expanding its catalog to include semaglutide as a research-use-only reference material.
Mechanism studied in research
Selective agonism of the GLP-1 receptor with a fatty-acid modification that extends its half-life — the reference point for single-receptor incretin research.
Areas of research investigation
- GLP-1 receptor signaling assays
- Comparative single- vs multi-agonist studies
- Peptide half-life and albumin-binding research
- Metabolic model systems
Laboratory handling
Research handling reconstitutes the lyophilized powder with bacteriostatic or sterile water and stores the solution refrigerated; the powder is kept frozen and protected from light.
Comparisons
Semaglutide research FAQ
Does TagPep sell semaglutide?
Semaglutide is on TagPep's research-catalog roadmap as a research-use-only reference material. Contact us to be notified when a documented batch is released.
How does semaglutide compare to tirzepatide in research?
Semaglutide is a single GLP-1 receptor agonist, while tirzepatide adds GIP-receptor activity; the two are frequently compared in incretin-receptor research. See our tirzepatide vs semaglutide reference page.
Research use only. Semaglutide is supplied as a laboratory reference material for in-vitro and research applications. It is not a drug, supplement or medical product, and is not intended for human or veterinary use, consumption, or clinical application.